Loading organizations...
§ Private Profile · Cary, NC, USA
Biopharmaceutical company developing clinical-stage therapeutics for CNS diseases, including selective cannabinoid compounds.
CeNeRx BioPharma is a specialty biopharmaceutical company developing clinical-stage therapeutics and preclinical treatments for central nervous system diseases, based in Cary, North Carolina. The organization specifically focuses on advancing novel pharmaceutical interventions for complex neurological and psychiatric conditions, including major depressive disorder, anxiety, epilepsy, glaucoma, spasticity, and severe pain. Operating with fewer than 25 employees and generating under $5 million in annual revenue, the now-defunct biotechnology enterprise successfully secured a total of $64.63 million in funding across multiple venture capital rounds and debt credit lines. This financial backing included significant investments from prominent industry figures such as investor Arthur Pappas of Pappas Capital, which directly supported the clinical advancement and licensing of proprietary drug candidates like CXB909 and TriRima. CeNeRx BioPharma was officially founded in 2005 by healthcare executives Mark Baric and Barry Brand.
CeNeRx BioPharma has raised $32.9M across 3 funding rounds.
CeNeRx BioPharma has raised $32.9M in total across 3 funding rounds.
CeNeRx BioPharma has raised $32.9M in total across 3 funding rounds.
CeNeRx BioPharma's investors include L Capital Partners, Omega Funds, Pappas Ventures, Perseus-Soros Biopharmaceutical Fund, Aisling Capital.
CeNeRx BioPharma has raised $32.9M across 3 funding rounds. Most recently, it raised $4.8M Other Equity in December 2011.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 9, 2011 | $4.8M Venture Round | — | L Capital Partners, Omega Funds, Pappas Ventures, Perseus Soros Biopharmaceutical Fund | Announced |
| Aug 13, 2010 | $13M Series C | — | L Capital Partners, Pappas Ventures, Perseus Soros Biopharmaceutical Fund | Announced |
| Oct 17, 2008 | $15M Venture Round | — | Aisling Capital, L Capital Partners, Pappas Ventures | Announced |